Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.4 - $0.56 $13,800 - $19,320
-34,500 Reduced 66.73%
17,200 $6,000
Q1 2024

May 15, 2024

SELL
$0.53 - $1.89 $24,963 - $89,019
-47,100 Reduced 47.67%
51,700 $27,000
Q4 2023

Feb 14, 2024

BUY
$1.22 - $5.24 $89,182 - $383,044
73,100 Added 284.44%
98,800 $124,000
Q3 2023

Nov 14, 2023

BUY
$2.75 - $5.17 $2,475 - $4,653
900 Added 3.63%
25,700 $87,000
Q2 2023

Aug 14, 2023

BUY
$4.09 - $8.29 $59,305 - $120,204
14,500 Added 140.78%
24,800 $106,000
Q1 2023

May 15, 2023

BUY
$4.89 - $10.53 $50,367 - $108,459
10,300 New
10,300 $83,000

Others Institutions Holding BIVI

About BIOVIE INC.


  • Ticker BIVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,165,300
  • Market Cap $86.3M
  • Description
  • BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...
More about BIVI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.